A practical reference on peptide research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-29 and is reviewed periodically as new material appears.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
=== Iodine === Iodine sublimes gradually and produces visible fumes on gentle heating at standard atmospheric temperature. It is possible to obtain liquid iodine at atmospheric pressure by controlling the temperature at just between the melting point and the boiling point of iodine. In forensic science, iodine vapor can reveal latent fingerprints on paper.
Breed identity is established through breed-registration records, while birthplace and rearing history are checked through the traceability system. This Wagyu designation is narrower than the Japanese origin category "domestic beef" (国産牛, kokusan-gyū), which generally applies when the animal was raised in Japan for longer than in any other country. Domestic beef therefore includes qualifying Wagyu as well as beef from Western-derived dairy breeds such as Holstein and Jersey, and from crosses between dairy and beef cattle. Beef from these dairy breeds and dairy–Wagyu crosses may be sold as domestic beef but does not qualify as Wagyu. Wagyu herds were also established outside Japan from cattle and genetic material exported beginning in the 1970s, particularly in the United States and Australia. Registered cattle in both countries include fullblood animals descended entirely from Japanese foundation stock as well as animals crossbred with other breeds. Breed associations maintain separate registers for these categories and use documented pedigrees, Wagyu ancestry percentages, and DNA parentage testing to determine registration. These are cattle-registration systems, whereas the Japanese guideline applies to the labeling of beef and also includes domestic birth and rearing requirements.
Following the release of his mixtape Hologram Panda with producer Dame Grease, Riff Raff told MTV that his upcoming Mad Decent second studio album would be titled Riff Raff, The Neon Icon, later shortened to Neon Icon. In February 2013 he told Complex that his second studio album is due out some time during the third quarter of 2013. On June 25, 2013, he released a single titled "Dolce & Gabbana", produced by DJ Carnage as the first single from Neon Icon, however two days later he announced that the song wouldn't be included on the album. He was also featured on Far East Movement's single "The Illest" around the same time. Then on July 12, 2013, he released another non album single titled "Mr. Popular", and four days later released the music video for the song. In August 2013, Riff Raff announced that he would be releasing a collaboration album with Action Bronson titled Galaxy Gladiators in 2014. On November 26, 2013, he released the first official single for Neon Icon titled "How To Be the Man" and produced by DJ Mustard. That same month, Riff Raff told Rolling Stone in an interview that leading up to the album's release he would release various "left-over" tracks from the album's recording sessions These notably included the Boi-1da produced "Real Boyz", featuring rappers OJ da Juiceman and Cap 1, as well as "Suckas Askin' Questions" with Lil Debbie and "Shoulda Won a Grammy" with Action Bronson. In March 2014, prior to the album's release, Rolling Stone included the album on their list of "27 Must-Hear Albums of 2014".
=== Impaired glucose tolerance === Impaired glucose tolerance (IGT) is diagnosed with an oral glucose tolerance test. According to the criteria of the World Health Organization and the American Diabetes Association, impaired glucose tolerance is defined as:
The synthesis of luciferin exemplifies another strategy of isolating reaction partners, which is to take advantage of rarely-occurring, natural groups such as the 1,2-aminothiol, which appears only when a cysteine is the final N' amino acid in a protein. Their natural selectivity and relative bioorthogonality is thus valuable in developing probes specific for these tags. The above reaction occurs between a 1,2-aminothiol and a 2-cyanobenzothiazole to make luciferin, which is fluorescent. This luciferin fluorescence may then be quantified by spectrometry following a wash, and used to determine the relative presence of the molecule bearing the 1,2-aminothiol. If the quantification of non-1,2-aminothiol-bearing protein is desired, the protein of interest may be cleaved to yield a fragment with a N' Cys that is vulnerable to the 2-CBT.
Sources: en.wikipedia.org
The Bolshevik government then established the Cheka (All-Russian Extraordinary Commission) secret police to eliminate anti–Bolshevik opposition in the country. Initially, there was strong opposition to the Bolshevik régime because they had not resolved the food shortages and material poverty of the Russian peoples as promised in October 1917. From that social discontent, the Cheka reported 118 uprisings, including the Kronstadt rebellion (7–17 March 1921) against the economic austerity of the War Communism imposed by the Bolsheviks. The principal obstacles to Russian economic development and modernisation were great material poverty and the lack of modern technology which were conditions that orthodox Marxism considered unfavourable to communist revolution. Agricultural Russia was sufficiently developed for establishing capitalism, but it was insufficiently developed for establishing socialism. For Bolshevik Russia, the 1921–1924 period featured the simultaneous occurrence of economic recovery, famine (1921–1922) and a financial crisis (1924). By 1924, considerable economic progress had been achieved and by 1926 the Bolshevik government had achieved economic production levels equal to Russia's production levels in 1913. Initial Bolshevik economic policies from 1917 to 1918 were cautious, with limited nationalisations of the means of production which had been private property of the Russian aristocracy during the Tsarist monarchy.
=== Nanoparticle-Protein Interactions === ITC is increasingly utilized to study protein-nanoparticle interactions by providing key insights into binding affinity (in the form of association constant), interaction mechanisms (quantified through binding enthalpy, binding entropy, and Gibbs free energy), and binding stoichiometry. These thermodynamic parameters from ITC can help assess structural modifications in proteins upon adsorption onto nanoparticle surfaces.
==== 2010s ==== In 2012, Starbucks had annual Frappuccino sales of over US$2 billion. In August 2012, the largest Starbucks in the US opened at the University of Alabama's Ferguson Centre. On June 25, 2013, Starbucks began to post calorie counts on menus for drinks and pastries in all of its U.S. stores. In July 2013, more than 10% of in-store purchases were made on customers' mobile devices via the Starbucks app. The company once again utilized the mobile platform when it launched the "Tweet-a-Coffee" promotion in October 2013. On this occasion, the promotion also involved Twitter and customers were able to purchase a US$5 gift card for a friend by entering both "@tweetacoffee" and the friend's handle in a tweet. Research firm Keyhole monitored the progress of the campaign; a December 2013 media article reported that 27,000 people had participated and US$180,000 of purchases had been made to date. In January 2014, as part of a change in compact direction, Starbucks management transitioned from a singular brand worldwide to focusing on locally relevant design for each store. In May 2014, Starbucks announced ongoing losses in the Australian market, which resulted in all remaining stores being sold to the Withers Group. In July 2017, Starbucks acquired the remaining 50% stake in its Chinese venture from long-term joint venture partners Uni-President Enterprises Corporation (UPEC) and President Chain Store Corporation (PCSC) for US$1.3 billion.
=== In early deuterostomes === The evolution of the gene family in primitive vertebrates is not well understood. For example, it has been shown that the gene coding for the ancestral relaxin peptide existed independently from the other genes of the insulin superfamily, i.e. INS and IGF genes, in the early chordate ancestor. It is known that the genes coding for RLN3 and INSL5 arose from one ancestral gene, and INSL3 shares origin with RLN2 and its multiple duplicates. However the exact origins of the family still remain to be elucidated. Other studies attempted to show the existence of relaxin family peptide genes in the tunicate Ciona, but it has not been shown that any of these are in the same linkage group as modern relaxin genes. Multiple relaxin genes have also been identified in Amphioxus, but again syntenic relationship of these genes to modern relaxin genes is unclear and experimental work is lacking. A relaxin-like peptide, previously referred to as "Gonad Stimulating Substance" was also characterized in the echinoderm Patiria pectinifera (starfish). There is evidence that the starfish peptide is involved in reproductive processes and functions via a GPCR, which supports its relatedness to vertebrate relaxins.
=== Rotigotine === Rotigotine (sold under the brand name Neupro, among others) is a dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS). In 2007, the Neupro patch was approved by the Food and Drug Administration (FDA) as the first transdermal patch treatment of Parkinson's disease in the United States. The drug had been established in 1980, and no prior polymorphism had been observed. In 2008, a more stable polymorph unexpectedly emerged, which was described as resembling "snow-like crystals". The new polymorph did not display any observable reduction in efficacy, but nonetheless, Schwarz Pharma recalled all Neupro patches in the United States and some in Europe. Those with remaining patches in Europe were told to refrigerate their stock, since refrigeration seemed to reduce crystallization rates. The patch was reformulated in 2012, as per FDA recommendations, and was reintroduced in the United States without requiring refrigeration.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.